日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS(G12D) inhibitor in KRAS LUAD.

SOS1 抑制剂 BI-3406 在体内显示出类似于基因消融的抗肿瘤活性,并且与 KRAS(G12D) 抑制剂在 KRAS LUAD 中具有协同作用

Baltanás Fernando C, Kramer-Drauberg Maximilian, García-Navas Rósula, Patrucco Enrico, Petrini Ettore, Arnhof Heribert, Olarte-San Juan Andrea, Rodríguez-Ramos Pablo, Borrajo Javier, Calzada Nuria, Castellano Esther, Mair Barbara, Kostyrko Kaja, Hofmann Marco H, Ambrogio Chiara, Santos Eugenio

SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR-mutant lung cancer

SOS1抑制剂可抑制奥希替尼耐药性的产生,从而在EGFR突变型肺癌中产生持久疗效。

Daley, Brianna R; Theard, Patricia L; Hughes, Jacob M; Finniff, Bridget A; Hofmann, Marco H; Kostyrko, Kaja; Schenk, Robyn L; Vieira, Heidi M; Askew, James W; Lewis, Robert E; Kortum, Robert L

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

通过对所有 KRAS 突变体进行药物治疗来扩大精准肿瘤学的应用范围

Hofmann, Marco H; Gerlach, Daniel; Misale, Sandra; Petronczki, Mark; Kraut, Norbert

Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models

IGF-1/IGF-2中和抗体Xentuzumab(BI 836845)联合恩扎卢胺在前列腺癌模型中的抗肿瘤活性

Weyer-Czernilofsky, Ulrike; Hofmann, Marco H; Friedbichler, Katrin; Baumgartinger, Rosa; Adam, Paul J; Solca, Flavio; Kraut, Norbert; Nguyen, Holly M; Corey, Eva; Liu, Gang; Sprenger, Cynthia C; Plymate, Stephen R; Bogenrieder, Thomas